RedHill is a distressed but option-rich biotech pivoting to partnerships, with Talicia providing survival value and RHB-102 offering speculative GLP-1 upside.
Overview
RedHill Biopharma is a high-risk specialty biopharma transitioning into a leaner, partnership-led model focused on GI, infectious disease, oncology, and GLP-1 side-effect management. Talicia, its branded H. pylori therapy, is the core commercial asset and is now co-commercialized through a Cumberland joint venture. Pipeline upside centers on RHB-102/Bekinda for GLP-1-induced nausea and opaganib in oncology. The story offers substantial optionality, but investors face liquidity pressure, dilution risk, Nasdaq compliance concerns, and dependence on partners to execute.